Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) announced Friday that an expert panel of the EU drug regulator, the European ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

AstraZeneca and Daiichi Sankyo have claimed approval in the EU ... The green light from the European Commission means that Enhertu (trastuzumab deruxtecan) can now be used for patients whose ...

The green light from the European Medicines Agency is the first ... In December, Astra and Daiichi withdrew an application in the EU for the drug to treat a type of lung cancer after feedback ...

The committee's recommendation was based on data from the TROPION-Breast01 trial, which also supported the US approval of Datroway in January.

Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sumao Manabe, DVM, PhD, will continue to serve as representative director and ...

Revenue growth was fueled by oncology products, particularly ENHERTU ... ENHERTU’s growth to offset Datroway’s shortfall. Daiichi Sankyo’s Q3 FY2024 results reflect strong performance ...

Narrow-moat Daiichi Sankyo’s third-quarter earnings were in line with our expectations. Despite its change in development strategy for recently approved Datroway (formerly known as Dato-DXd), we ...

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1 ...

In a report released yesterday, Seiji Wakao from J.P. Morgan maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report), with ...

Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) announced Friday that an expert panel of the EU drug regulator, the European Medicines ... s Committee for Medicinal Products for Human Use (CHMP ...